KRYSTAL BIOTECH INC
KRYSNASDAQTrading Snapshot
- Day Range
- $323.74 – $332.31
- 52-Week Range
- $133.00 – $382.54
- Volume
- $1.70B
- Avg Volume
- $1.59B
- Shares Outstanding
- 29.5M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $389M
- Last Q Revenue
- $119M
- P/E Ratio
- 40.3
- P/S Ratio
- 22.1x
- EPS (TTM)
- $7.98
- Dividend Yield
- —
Why Investors Own KRYS
- ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About KRYSTAL BIOTECH INC
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market capitalization of
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run
Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectations. Krystal Biotech has returned roughly 5x over the past 5 years, which puts extra focus on whether the current share price still offers an appealing entry point or mainly reflects past success. Ongoing adoption of its genetic medicine platform can support the current valuation, while concerns...
Krystal Biotech, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Krystal Biotech, Inc.
Earnings Calendar and Analysis for This Week (June 8-12)
Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.